Sheryl Kingsberg: Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses from the RECONNECT Studies (Introduced by C. Egarter)

Sheryl Kingsberg: Bremelanotide (BMT) for Hypoactive Sexual Desire Disorder (HSDD): Efficacy Analyses from the RECONNECT Studies (Introduced by C. Egarter)
Symposium: (OL02) Hypoactive sexual desire disorder: addressing an unmet medical need
Presented at the 13 Congress of the European Society of Gynecology – 2019
April 2, 2020

This site uses cookies for functional and analytical purposes. Set cookie preference

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close